Antibody Therapy for Chronic Lymphocytic Leukemia

Seminars in Hematology

Volumn 45, Issue 2, 2008, Pages 95-103

  Christian, Beth A ^a   Lin, Thomas S ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; APOLIZUMAB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; HUMAX; LUMILIXIMAB; MONOCLONAL ANTIBODY; OFATUMUMAB; PENTOSTATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ARTICLE; BLOOD TOXICITY; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DRUG DOSE ESCALATION; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUGS, INVESTIGATIONAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; PENTOSTATIN; VIDARABINE;

EID: 41149101246     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2008.02.001     Document Type: Article

References (64)

1. Kitada S., Andersen J., Akar S., Zapata J.M., Takayama S., Krajewski S., et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations witi in vitro and in vivo chemoresponses. Blood 91 (1998) 3379-3389
2. Golay J., Zaffaroni L., Vaccari T., Lazzari M., Borleri G.M., Bernasconi S., et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95 (2000) 3900-3908
3. Rai K.R., Peterson B.L., Appelbaum F.R., Kolitz J., Elias L., Shepherd L., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1750-1757
4. O'Brien S.M., Kantarjian H., Thomas D.A., Giles F.J., Freireich E.J., Cortes J., et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19 (2001) 2165-2170
5. Treon S.P., Mitsiades C., Mitsiades N., Young G., Doss D., Schlossman R., et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 24 (2001) 263-271
6. Byrd J.C., Kitada S., Flinn I.W., Aron J.L., Pearson M.D., Lucas D., et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: Evidence of caspase activation and apoptosis induction. Blood 99 (2002) 1038-1043
7. Pedersen I.M., Buhl A.M., Klausen P., Geisler C.H., and Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 99 (2002) 1314-1319
8. Golay J., Lazzari M., Facchinetti V., Bernasconi S., Borleri G.M., Barbui T., et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59. Blood 98 (2001) 3383-3389
9. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16 (1998) 2825-2833
10. Nguyen D.T., Amess J.A., Doughty H., Hendry L., and Diamond L.W. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients. Eur J Haematol 62 (1999) 76-82
11. Winkler U., Jensen M., Manzke O., Schulz H., Diehl V., and Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94 (1999) 2217-2224
12. Ladetto M., Bergui L., Ricca I., Campana S., Pileri A., and Tarella C. Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients. Med Oncol 17 (2000) 203-210
13. Huhn D., von Schilling C., Wilhelm M., Ho A.D., Hallek M., Kuse R., et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98 (2001) 1326-1331
14. Itala M., Geisler C.H., Kimby E., Juvonen E., Tjonnfjord G., Karlsson K., et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: Results from a Nordic multicentre study. Eur J Haematol 69 (2002) 129-134
15. Thomas D.A., O'Brien S., Giles F.J., Cortes J., Faderl S., Kantarjian H., et al. Single agent rituxan in early stage chronic lymphocytic leukemia (CLL). Blood 98 (2001) 364a
16. Hainsworth J.D., Litchy S., Barton J.H., Houston G.A., Hermann R.C., Bradof J.E., et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie earl Cancer Research Network. J Clin Oncol 21 (2003) 1746-1751
17. Byrd J.C., Murphy T., Howard R.S., Lucas M.S., Goodrich A., Park K., et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19 (2001) 2153-2164
18. Byrd J.C., Smith L., Hackbarth M.L., Flinn I.W., Young D., Proffitt J.H., et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 63 (2003) 36-38
19. Byrd J.C., Peterson B.L., Morrison V.A., Park K., Jacobson R.J., Hoke E., et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101 (2003) 6-14
20. Byrd J.C., Gribben J.G., Peterson B.L., Grever M.R., Lozanski G., Lucas D.M., et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol 24 (2006) 437-443
21. Byrd J.C., Rai K., Peterson B.L., Appelbaum F.R., Morrison V.A., Kolitz J.E., et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previoulsy untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105 (2005) 49-53
22. Schulz H., Klein S.K., Rehwald U., Reiser M., Hinke A., Knauf W.U., et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 100 (2002) 3115-3120
23. Wierda W., O'Brien S., Wen S., Faderl S., Garcia-Manero G., Thomas D.A., et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 4070-4078
24. Keating M.J., O'Brien S., Albitar M., Lerner S., Plunkett W., Giles F.J., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 4079-4088
25. Kay N.E., Geyer S.M., Call T.G., Shanafelt T.D., Zent C.S., Jelinek D.F., et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chroinc lymphocytic leukemia. Blood 109 (2007) 405-411
26. Shanafelt T.D., Lin T.S., Geyer S.M., Zent C.S., Leung N., Kabat B., et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 109 (2007) 2291-2298
27. Flynn J.M., and Byrd J.C. Campath-1H monoclonal antibody therapy. Curr Opin Oncol 12 (2000) 574-581
28. Hale G., Bright S., Chumbley G., Hoang T., Metcalf D., Munro A.J., et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 62 (1983) 873-882
29. Hale G., Swirsky D., Waldmann H., and Chan L.C. Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation. Br J Haematol 60 (1985) 41-48
30. Hale G., Dyer M.J., Clark M.R., Phillips J.M., Marcus R., Riechmann L., et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 2 (1988) 1394-1399
31. Salisbury J.R., Rapson N.T., Codd J.D., Rogers M.V., and Nethersell A.B. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol 47 (1994) 313-317
32. Rowan W., Tite J., Topley P., and Brett S.J. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 95 (1998) 427-436
33. Bowen A.L., Zomas A., Emmett E., Matutes E., Dyer M.J., and Catovsky D. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 96 (1997) 617-619
34. Keating M.J., Flinn I., Jain V., Binet J.-L., Hillmen P., Byrd J.C., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 99 (2002) 3554-3561
35. Osterborg A., Fassas A.S., Anagnostopoulos A., Dyer M.J., Catovsky D., and Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 93 (1996) 151-153
36. Osterborg A., Dyer M.J., Bunjes D., Pangalis G.A., Bastion Y., Catovsky D., et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia: European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15 (1997) 1567-1574
37. Rai K.R., Coutre S., Rizzieri D., Gribben J.G., Flinn I., Rabinowe S., et al. Efficacy and safety of alemtuzumab (Campath-1H) in refractory B-CLL patients treated on a compassionate basis. Blood 98 (2001) 365a
38. Moreton P., Kennedy B., Lucas G., Leach M., Rassam S.M., Haynes A.P., et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23 (2005) 2971-2979
39. Dohner H., Fischer K., Bentz M., Hansen K., Benner A., Cabot G., et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85 (1995) 1580-1589
40. Dohner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1910-1916
41. Lozanski G., Heerema N.A., Flinn I.W., Smith S., Harbison J., Webb J., et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103 (2004) 3278-3281
42. Stilgenbauer S., and Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 347 (2002) 452-453
43. Stilgenbauer S., Krober A., Busch R., Eichhorst B.F., Kienle D., Winkler D., et al. 17p deletion predicts for inferior overall survival after fludarabine - based first line therapy in chronic lymphocytic leukemia: First analysis of genetics in the CLL4 trial of the GCLLSG. Blood 106 (2005) 715 (abstr)
44. Lundin J., Kimby E., Bjorkholm M., Broliden P.A., Celsing F., Hjalmar V., et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100 (2002) 768-773
45. Hillmen P., Skotnicki A., Robak T., Jaksic B., Dmoszynska A., Sirard C., et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25 (2007) 5616-5623
46. Kennedy B., Rawstron A., Carter C., Ryan M., Speed K., Lucas G., et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99 (2002) 2245-2247
47. Elter T., Borchmann P., Schulz H., Reiser M., Trelle S., Schnell R., et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: Results of a phase II trial. J Clin Oncol 23 (2005) 7024-7031
48. Wierda W.G., O'Brien S., Faderl S., Ferrajoli A., Ravandi-Kashani F., Cortes J., et al. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL. Blood 108 (2006) 14a
49. O'Brien S.M., Kantarjian H.M., Thomas D.A., Cortes J., Giles F.J., Wierda W.G., et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98 (2003) 2657-2663
50. Wendtner C.M., Ritgen M., Schweighofer C.D., Fingerle-Rowson G., Campe H., Jager G., et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission: Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18 (2004) 1093-1101
51. Schweighofer C., Ritgen M., Eichhorst B.F., Busch R., Kneba M., Hallek M., et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Blood 108 (2006) 14a
52. Rai K.R., Byrd J.C., Peterson B.L., Gautier M., and Larson R.A. Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB study 19901. Blood 102 (2003) 2506 (abstr)
53. Stilgenbauer S., Winkler D., Krober A., Kienle D., Hallek M., Hensel M., et al. Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL: Interim analysis of the CLL2H study of the German CLL Study Group (GCLLSG). Blood 104 (2004) 478 (abstr)
54. Pathan N., Hopkins M., Saven A., Reff M.E., Grint P., and Hariharan K. Induction of apoptosis by IDEC-152 (anti-CD23) in chronic lymphocytic leukemia. Leuk Lymphoma 42 suppl 1 (2001) 133N
55. Byrd J.C., O'Brien S., Flinn I.W., Kipps T.J., Weiss M.A., Rai K., et al. Phase I study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 13 (2007) 4448-4455
56. Byrd J.C., Castro J., O'Brien S., Flinn I.W., Forero-Torres A., Kipps T.J., et al. Comparison of results from a phase 1/2 study of lumiliximab (anti-CD23) in combination with FCR for patients with relapsed CLL with published FCR results. Blood 108 (2006) 14a
57. Coiffier B., Tilly H., Pedersen L.M., Plesner T., Frederiksen H., van Oers M.H.J., et al. Significant correlation between survival endpoints and exposure to ofatumumab (HuMax-CD20) in chronic lymphocytic leukemia. Blood 108 (2006) 804a-805a
58. Stein R., Belisle E., Hansen H.J., and Goldenberg D.M. Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2. Cancer Immunol Immunother 37 (1993) 293-298
59. Leonard J.P., Coleman M., Ketas J.C., Chadburn A., Ely S., Furman R.R., et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 21 (2003) 3051-3059
60. Kostelny S.A., Link B.K., Tso J.Y., Vasquez M., Jorgensen B.H., Wang H.G., et al. Humanization and characterization of the anti-HLA-DR antibody 1D10. Int J Cancer 93 (2001) 556-565
61. Gingrich R.D., Dahle C.E., Hoskins K.F., and Senneff M.J. Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes. Blood 75 (1990) 2375-2387
62. Link B.K., Wang H.G., Byrd J.C., Leonard J.P., Davis T.A., Flinn I., et al. Phase I study of Hu1D10 monoclonal antibody in patients with B-cell lymphoma. Proc Am Soc Clin Oncol 20 (2001) 284a
63. Link B.K., Kahl B., Czuczman M.S., Powell B.L., Bartlett N., Leonard J.P., et al. A phase II study of Remitogen (Hu1D10), a humanized monoclonal antibody in patients with relapsed or refractory follicular, small lymphocytic, or marginal zone/MALT B-cell lymphoma. Blood 98 (2001) 606a
64. Lin T.S., Stock W., Lucas M.S., Porcu P., Abhyankar V.V., Jefferson S.K., et al. A phase I dose escalation study of apolizumab (Hu1D10) using a stepped up dosing schedule in patients with chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL). Blood 100 (2002) 802a